Pluristem Therapeutics Inc (PSTI)

[patentminer2013]

Pluristem Therapeutics Inc. (PSTI) Given a $4.00 Price Target at HC Wainwright
March 26th, 2017 • 0 comments • Filed Under • by ABMN Staff


Pluristem Therapeutics logoPluristem Therapeutics Inc. (NASDAQ:PSTI) has been assigned a $4.00 price objective by stock analysts at HC Wainwright in a research report issued on Saturday. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 230.58% from the stock’s current price.

Several other equities analysts have also issued reports on the company. Maxim Group set a $3.00 price objective on Pluristem Therapeutics and gave the stock a “buy” rating in a report on Tuesday, January 17th. Zacks Investment Research lowered Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 3rd. Finally, FBR & Co reaffirmed an “outperform” rating and set a $6.00 price objective on shares of Pluristem Therapeutics in a report on Friday, December 23rd.

Pluristem Therapeutics (NASDAQ:PSTI) traded up 0.83% during trading on Friday, reaching $1.21. The company had a trading volume of 135,908 shares. Pluristem Therapeutics has a 1-year low of $1.04 and a 1-year high of $1.85. The firm has a 50-day moving average of $1.15 and a 200-day moving average of $1.42. The stock’s market capitalization is $116.24 million.



A hedge fund recently raised its stake in Pluristem Therapeutics stock. Renaissance Technologies LLC increased its position in Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 8.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,424,800 shares of the company’s stock after buying an additional 113,300 shares during the period. Renaissance Technologies LLC owned 1.76% of Pluristem Therapeutics worth $2,037,000 as of its most recent SEC filing. Institutional investors and hedge funds own 3.05% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.